BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 17310998)

  • 1. Epigenetic silencing of HSulf-1 in ovarian cancer:implications in chemoresistance.
    Staub J; Chien J; Pan Y; Qian X; Narita K; Aletti G; Scheerer M; Roberts LR; Molina J; Shridhar V
    Oncogene; 2007 Jul; 26(34):4969-78. PubMed ID: 17310998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of expression of a new member of the DNAJ protein family confers resistance to chemotherapeutic agents used in the treatment of ovarian cancer.
    Shridhar V; Bible KC; Staub J; Avula R; Lee YK; Kalli K; Huang H; Hartmann LC; Kaufmann SH; Smith DI
    Cancer Res; 2001 May; 61(10):4258-65. PubMed ID: 11358853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of HSulf-1 expression by variant hepatic nuclear factor 1 in ovarian cancer.
    Liu P; Khurana A; Rattan R; He X; Kalloger S; Dowdy S; Gilks B; Shridhar V
    Cancer Res; 2009 Jun; 69(11):4843-50. PubMed ID: 19487294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dominant-negative histone H3 lysine 27 mutant derepresses silenced tumor suppressor genes and reverses the drug-resistant phenotype in cancer cells.
    Abbosh PH; Montgomery JS; Starkey JA; Novotny M; Zuhowski EG; Egorin MJ; Moseman AP; Golas A; Brannon KM; Balch C; Huang TH; Nephew KP
    Cancer Res; 2006 Jun; 66(11):5582-91. PubMed ID: 16740693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic modulation of tumor suppressor CCAAT/enhancer binding protein alpha activity in lung cancer.
    Tada Y; Brena RM; Hackanson B; Morrison C; Otterson GA; Plass C
    J Natl Cancer Inst; 2006 Mar; 98(6):396-406. PubMed ID: 16537832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypoxic silencing of tumor suppressor RUNX3 by histone modification in gastric cancer cells.
    Lee SH; Kim J; Kim WH; Lee YM
    Oncogene; 2009 Jan; 28(2):184-94. PubMed ID: 18850007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficient inhibition of an intraperitoneal xenograft model of human ovarian cancer by HSulf-1 gene delivered by biodegradable cationic heparin-polyethyleneimine nanogels.
    Liu P; Gou M; Yi T; Xie C; Qi X; Zhou S; Deng H; Wei Y; Zhao X
    Oncol Rep; 2012 Feb; 27(2):363-70. PubMed ID: 22086394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The enhanced antitumor effects of biodegradable cationic heparin-polyethyleneimine nanogels delivering HSulf-1 gene combined with cisplatin on ovarian cancer.
    Liu P; Gou M; Yi T; Qi X; Xie C; Zhou S; Deng H; Wei Y; Zhao X
    Int J Oncol; 2012 Oct; 41(4):1504-12. PubMed ID: 22825572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cell type-specific methylation of an intronic CpG island controls expression of the MCJ gene.
    Strathdee G; Davies BR; Vass JK; Siddiqui N; Brown R
    Carcinogenesis; 2004 May; 25(5):693-701. PubMed ID: 14729589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypomethylation of the synuclein gamma gene CpG island promotes its aberrant expression in breast carcinoma and ovarian carcinoma.
    Gupta A; Godwin AK; Vanderveer L; Lu A; Liu J
    Cancer Res; 2003 Feb; 63(3):664-73. PubMed ID: 12566312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic silencing of miR-130b in ovarian cancer promotes the development of multidrug resistance by targeting colony-stimulating factor 1.
    Yang C; Cai J; Wang Q; Tang H; Cao J; Wu L; Wang Z
    Gynecol Oncol; 2012 Feb; 124(2):325-34. PubMed ID: 22005523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomic screening for genes silenced by DNA methylation revealed an association between RASD1 inactivation and dexamethasone resistance in multiple myeloma.
    Nojima M; Maruyama R; Yasui H; Suzuki H; Maruyama Y; Tarasawa I; Sasaki Y; Asaoku H; Sakai H; Hayashi T; Mori M; Imai K; Tokino T; Ishida T; Toyota M; Shinomura Y
    Clin Cancer Res; 2009 Jul; 15(13):4356-64. PubMed ID: 19549772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic and HIF-1 regulation of stanniocalcin-2 expression in human cancer cells.
    Law AY; Lai KP; Ip CK; Wong AS; Wagner GF; Wong CK
    Exp Cell Res; 2008 May; 314(8):1823-30. PubMed ID: 18394600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of HSulf-1 expression enhances tumorigenicity by inhibiting Bim expression in ovarian cancer.
    He X; Khurana A; Roy D; Kaufmann S; Shridhar V
    Int J Cancer; 2014 Oct; 135(8):1783-9. PubMed ID: 24596063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histone modification in the TGFbetaRII gene promoter and its significance for responsiveness to HDAC inhibitor in lung cancer cell lines.
    Osada H; Tatematsu Y; Sugito N; Horio Y; Takahashi T
    Mol Carcinog; 2005 Dec; 44(4):233-41. PubMed ID: 16163707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transcriptional silencing of the DLC-1 tumor suppressor gene by epigenetic mechanism in gastric cancer cells.
    Kim TY; Jong HS; Song SH; Dimtchev A; Jeong SJ; Lee JW; Kim TY; Kim NK; Jung M; Bang YJ
    Oncogene; 2003 Jun; 22(25):3943-51. PubMed ID: 12813468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of HSulf-1: The Missing Link between Autophagy and Lipid Droplets in Ovarian Cancer.
    Roy D; Mondal S; Khurana A; Jung DB; Hoffmann R; He X; Kalogera E; Dierks T; Hammond E; Dredge K; Shridhar V
    Sci Rep; 2017 Feb; 7():41977. PubMed ID: 28169314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased expression of unmethylated CDKN2D by 5-aza-2'-deoxycytidine in human lung cancer cells.
    Zhu WG; Dai Z; Ding H; Srinivasan K; Hall J; Duan W; Villalona-Calero MA; Plass C; Otterson GA
    Oncogene; 2001 Nov; 20(53):7787-96. PubMed ID: 11753657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methylation mediated silencing of TMS1/ASC gene in prostate cancer.
    Das PM; Ramachandran K; Vanwert J; Ferdinand L; Gopisetty G; Reis IM; Singal R
    Mol Cancer; 2006 Jul; 5():28. PubMed ID: 16848908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential modulation of nuclear texture, histone acetylation, and MDR1 gene expression in human drug-sensitive and -resistant OV1 cell lines.
    Yatouji S; El-Khoury V; Trentesaux C; Trussardi-Regnier A; Benabid R; Bontems F; Dufer J
    Int J Oncol; 2007 Apr; 30(4):1003-9. PubMed ID: 17332941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.